Glutathione Levels and Glutathione-Glutamate Correlation in Patients with Treatment-Resistant Schizophrenia

Yusuke Iwata, M.D., Ph.D. a, b, c, d) *, Shinichiro Nakajima, M.D., Ph.D. a, d) *, Eric Plitman, Ph.D. a, e), Peter Truong M.Eng. a), Ali Bani-Fatemi Ph.D. e), Fernando Caravaggio, Ph.D. a), Julia Kim, B.Sc. a, e), Parita Shah, B.Sc. a, e), Wanna Mar M.A. a), Sofia Chavez, Ph.D. a), Gary Remington, M.D., Ph.D. b, e, f, g), Philip Gerretsen, M.D., Ph.D. a, b, c, g), Vincenzo De Luca, M.D., Ph.D. b, c, g), Napapon Sailasuta, Ph.D. a, b, h), Ariel Graff-Guerrero, M.D., Ph.D. a, b, c, g)

a) Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
b) Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
c) Geriatric Mental Health Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
d) Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan
e) Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
f) Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
g) Campbell Institute Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
h) Department of Tropical Medicine, University of Hawaii, Honolulu, Hawaii, United States

* These authors equally contributed to this work.


Corresponding author:
Dr. Ariel Graff-Guerrero M.D., Ph.D.
Multimodal Imaging Group, Research Imaging Centre,
Centre for Addiction and Mental Health.
250 College Street, Toronto, Ontario, M5T 1R8, Canada
Tel: 416-535-8501 ext. 4834
Email: ariel_graff@yahoo.com.mx

Funding Support:
This work was funded by Ontario Mental Health Foundation (OMHF) Type A grant, Canadian Institutes of Health Research (CIHR) grants MOP-142493 and MOP-141968.
Abstract

Treatment-resistant schizophrenia has been suggested to involve glutamatergic dysfunction. Glutathione (GSH), a dominant antioxidant, is known to be involved in glutamatergic neurotransmission. To date, no study has examined GSH levels in patients with treatment-resistant schizophrenia. The aim of this study was to examine GSH levels in the dorsal anterior cingulate cortex (dACC) of patients with treatment-resistant schizophrenia. Patients with schizophrenia were categorized into three groups with respect to their antipsychotic response: (1) clozapine (CLZ) non-responders, (2) CLZ responders, and (3) first-line responders (FLR). GSH and glutamine+glutamate (Glx) levels were measured using 3T proton magnetic resonance spectroscopy. Firstly, dACC GSH levels were compared among the patient groups and healthy controls (HCs). Further, relationships between GSH and Glx levels were compared between the groups and GSH levels were explored stratifying the patient groups based on the glutamate-cysteine ligase catalytic (GCLC) subunit polymorphism. There was no difference in GSH levels between the groups. FLR showed a more negative relationship between GSH and Glx levels in the dACC compared to HCs. There were no effects of GCLC genotype on the GSH levels. However, CLZ responders had a higher ratio of high-risk GCLC genotype compared to CLZ non-responders. This study demonstrated different relationships between GSH and Glx in the dACC between groups. In addition, the results suggest a potential link between CLZ response and GCLC genotype. However, it still remains unclear how these differences are related to the underlying pathophysiology of schizophrenia subtypes or the mechanisms of action of CLZ.

Key Words: schizophrenia, oxidative stress, glutamate, glutathione, treatment-resistant
Introduction

Schizophrenia is a debilitating illness, which affects approximately 1% of the global population. Most antipsychotics share the property of dopamine antagonism and play a central role in the pharmacological treatment of schizophrenia. Based on the clinical effects of antipsychotics, the dopamine hypothesis of schizophrenia was proposed, positing that elevated dopaminergic function plays a central role in the pathophysiology of schizophrenia. In support, one meta-analysis of positron emission topography (PET) studies demonstrated that presynaptic dopamine function is higher in patients with schizophrenia compared to healthy controls (HCs). Indeed, greater endogenous dopamine levels at D_2 receptors have been demonstrated in the dorsal striatum of patients with schizophrenia, and these elevated dopamine levels positively predict response to antipsychotics. However, it is also known that about one third of patients with schizophrenia do not respond to non-clozapine (CLZ) antipsychotics; these patients are considered to have treatment-resistant schizophrenia (TRS). Notably, previous [^{18}F]-DOPA PET studies have demonstrated lower dopamine synthesis capacity in the striatum of patients with TRS compared to those who respond to first-line antipsychotics (first-line responders: FLR) i.e. antipsychotics other than clozapine, suggesting that TRS represents a different underlying pathophysiology than dopamine dysfunction.

It has been proposed that the glutamate (Glu) hypothesis may play a role in the pathophysiology of TRS. Studies noted elevations of Glu levels in the dorsal anterior cingulate cortex (dACC) of patients with TRS compared to FLR or HCs using proton magnetic resonance spectroscopy (^1^H-MRS). In addition, a recent prospective study demonstrated that higher Glu levels in the pregenual ACC (pgACC) before antipsychotic treatment were related to treatment failure after 4 weeks of amisulpride treatment in patients with first-episode psychosis. Furthermore, our group previously reported that patients with schizophrenia, who were resistant to other antipsychotics as well as CLZ (CLZ non-responders), had higher glutamine+glutamate (Glx) levels in the dACC compared to HCs. These findings suggest that the pathophysiology of TRS may be related to glutamatergic rather than dopaminergic dysfunction.

Glutathione (GSH) is another neurometabolite that plays a role in the glutamatergic system. It is known that GSH is involved in glutamatergic neurotransmission by potentiating N-methyl D-aspartate (NMDA) receptor functioning through activating the redox modulatory site. Further, it has been demonstrated that the GSH-cycle molds the activity of synaptic Glu. In addition to its effects on glutamatergic neurotransmission, GSH is known to be a dominant antioxidant compound in the brain. Notably, oxidative stress and antioxidant defence dysfunction have been proposed as one of the putative mechanisms underlying schizophrenia. It has been reported that GSH levels are reduced in the blood and in post-mortem brains within this population; in addition, a genetic study suggested relationships between polymorphisms of glutamate-cysteine ligase catalytic subunit (GCLC), a subunit of GSH synthesis enzymes, and risk of schizophrenia. That study reported that the high-risk GCLC genotype was related to lower GSH levels in the pgACC regardless of illness condition (schizophrenia or HCs). Moreover, they also found that GSH levels were positively correlated with Glu levels in the ACC in those with low risk, but not in those with high-risk. Further,
a recent meta-analysis of $^1$H-MRS studies revealed lower ACC GSH levels in patients with schizophrenia compared to HCs, with a modest effect size (ES=0.26). Interestingly, one study reported that patients with schizophrenia taking CLZ had higher plasma GSH levels than those taking risperidone. Another study reported that the non-functional polymorphism of glutathione S-transferases was related to higher susceptibility to TRS. These results suggest a potential link of GSH metabolism to the pathophysiology of TRS and the effects of CLZ. However, to date no study has examined ACC GSH levels, and their relationship with ACC Glu levels, in patients with TRS.

In this study, we sought to examine the relationships between antipsychotic response/resistance and GSH levels in the dACC of patients with schizophrenia. We chose the dACC as the region of interest as post-mortem studies reporting altered GSH levels have focused on this region. Further, we classified patients with schizophrenia into the following three groups based on their response to antipsychotics: (1) CLZ non-responders, (2) CLZ responders, and (3) FLR. We compared GSH levels in the dACC among the patient groups and HCs. We also examined relationships between dACC GSH levels and symptom severity. Furthermore, stratifying the patients based on the GCLC polymorphism, dACC GSH levels and the associations between GSH and Glu levels in the dACC were explored in the whole patient sample.

Methods

Participants

This was a single-centre cross-sectional study conducted at the Centre for Addiction and Mental Health (CAMH) between 2014 and 2017. All participants were recruited from the CAMH Research Registry, study advertisements, or referrals. Each participant provided written informed consent, was screened for drugs of abuse as part of the screening visit, and received a stipend for their involvement. The study was approved by the Research Ethics Board at CAMH. Patients with a DSM-IV/SCID diagnosis of schizophrenia spectrum disorders were recruited, and antipsychotic treatment-resistance was defined by the modified Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus criteria. CLZ non-responder criteria included: (1) current treatment of CLZ, (2) a history of treatment failure to optimal treatment with at least 2 previous non-CLZ antipsychotics, and (3) subsequent treatment failure with CLZ after patients had taken CLZ for $\geq$6 weeks at a minimum dose of 300 mg/day. CLZ responder criteria included: (1) current treatment of CLZ, (2) a history of treatment failure to optimal treatment with at least 2 previous non-CLZ antipsychotics, and (3) subsequent treatment response to CLZ. FLR criteria included: (1) current treatment of a single non-CLZ antipsychotic, and (2) treatment response. Lastly, HCs met inclusion criteria if they had no history of psychiatric illness, as assessed by the Mini-International Neuropsychiatric Interview (MINI). Exclusion criteria for all groups consisted of: (1) substance abuse or dependence within the past 6 months; (2) positive urine drug screen at inclusion or prior to MRI scanning; (3) history of head trauma resulting in loss of consciousness $\geq$30 minutes; (4) an unstable physical illness or neurological disorder; or (5) current administration of lamotrigine, topiramate, or memantine. The definition of optimal antipsychotic treatment and the assessment procedures of antipsychotic treatment response and failure were detailed elsewhere.
MRI acquisition

All participants were scanned in a 3T 750 MR scanner (General Electric HealthCare, Wisconsin, US) with an 8-channel receive only head coil for reception and body coil for transmission at CAMH. For MRS voxel placement and gray-white matter segmentation a 3-dimensional IR-prepared T1-weighted magnetic resonance imaging (MRI) scan (BRAVO, TE=3.00 ms, TR=6.74 ms, TI=650ms, flip angle=8°, FOV=230 mm, 256×256 matrix, slice thickness=0.9 mm) was performed.

$^1$H-MRS acquisition

GSH spectra were obtained using the interleaved J-difference editing method (MEGA-PRESS, TE=68 ms, TR=1500 ms, spectral width=5000 Hz, 4096 data-points, 512 water-suppressed, 16 water-unsuppressed averages, 8 NEX), as previously described. A voxel with the size of 24 mL (20×40×30 mm$^3$) was placed over the dACC (Supplementary Figure 1). Shimming was performed using the manufacture automated shimming routine (AUTOSHIM), to achieve a full-width at half maximum (FWHM) ≤10 Hz. Two frequency selective RF pulses, with a pulse width of 14.4 ms, were used to invert the strongly coupled resonances of $\alpha$ (4.56 ppm) and $\beta$ (2.95 ppm) protons of the cysteinyl moiety of GSH. The frequencies of the editing pulses alternated between editing “on” and editing “off” which were centered at 4.56 ppm and 7.50 ppm, respectively. Raw MRS data from each coil was combined in the time domain based on coil sensitivity from the unsuppressed water signal, weighted by the sum of squares of the signal intensities from each coil. Upon subtraction of the “on” and “off” conditions, the uncontaminated GSH resonance at 2.95 ppm is observed. IDL-based software (XsOs-NMR) was used to quantify the GSH and unsuppressed water peaks.

The data was spectrally apodized with a 3 Hz Gaussian filter and then zero filled to 8192 points, prior to being Fourier transformed. GSH resonances at 2.95ppm were modeled as a singlet using pseudo-voight fitting functions and then fitted in the frequency domain using a highly optimized public-domain Levenberg-Marquardt nonlinear least-squares minimization routine, MPFIT (Supplementary Figure 2). In this study, the ratio of GSH to unsuppressed water peak (GSH/H$_2$O) areas is reported in institutional units (IU). Spectra quality was visually assessed by two authors (PT and NS).

Glu and Glx spectra were collected using point-resolved spectroscopy (PRESS, TE=35 ms, TR=2000 ms, spectral width=5000 Hz, 4096 data-points, 128 water-suppressed, 16 water-unsuppressed averages, 8 NEX). Shimming was performed to achieve a full-width at FWHM ≤12 Hz, measured on the unsuppressed water signal from the voxel. $^1$H-MRS voxels were placed on the bilateral dACC (voxel size=9.0 mL [30×20×15 mm$^3$]) (Figure 1). The detailed voxel placement procedures, locations of the $^1$H-MRS voxels, and representative spectra were provided elsewhere. Water-suppressed spectra were analyzed using LCModel version 6.3-0E. Glu levels were estimated with a field appropriate LCmodel provided basis set with matching TE (=35 ms). Then, metabolite levels were normalized to unsuppressed water signal. Metabolite levels were expressed as IU. %SD values ≥20 % were deemed poor quality and excluded from subsequent analyses.

T1-weighted MRI scans were segmented into gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF) using the FIRST tool from FSL. A MATLAB-based software package named “Gannet” (http://www.gabamrs.com) was used to create a mask of the voxel size and location on the segmented T1-weighted image, permitting correction of neurometabolite level for fractions of CSF in the ROI. Corrected levels=water reference levels* (100[Total volume]/100-CSF%=[GM%+WM%]).
Genotyping of GCLC tri-nucleotide polymorphism

Classification into high-risk or low-risk genotype was based on the number of GAG repeats as described by Gysin et al. (7/8, 8/8, 8/9, and 9/9 and 7/7 and 7/9 respectively) \(^\text{27}\). Detailed genotyping procedures are provided in the Supplementary Methods.

Statistical analysis

Statistical analyses were performed using SPSS Statistics version 25 (IBM Corporation). Firstly, clinical and demographic characteristics, FWHM values, and GM ratios (GM/[GM+WM]) within GSH voxel were compared between the groups. Then, relationships between GSH levels, clinical and demographic characteristics, and GM ratios were examined within each group. A significance level of \(p<0.05/\text{number of comparisons} \) was utilized in each group analyses.

For primary analyses, group differences in dACC GSH levels were examined. Firstly, GSH levels were compared between the groups using an analysis of variance (ANOVA). Then, analyses of covariance were performed controlling for age, GM ratio, FWHM, and characteristics that showed associations with GSH levels. For exploratory analyses, correlations between GSH levels and symptom severity scores were examined with using a significance threshold of \(p<0.0125\) (0.05/4), owing to the number of comparisons (PANSS total and 3 subscale scores) in the whole patient sample and within each group by using Spearman’s correlation. In addition, we assessed relationships between GSH and glutamatergic neurometabolite levels within each group with using a significance threshold of \(p<0.0125\) (0.05/4). Further, differences in associations between dACC GSH and glutamatergic neurometabolite levels among groups were examined by using Fisher’s \(r\)-to-\(z\) calculation with using a significance threshold of \(p<0.0083\) (0.05/6\(^\text{[4]}\)), owing to the four group comparisons.

As the genetic samples were collected only for the patient groups, a two-way ANOVA was conducted to examine effects of the GCLC genotype (high-risk or low-risk) and group of patients (CLZ non-responders, CLZ responders, or FLR) on GSH levels only for the patient samples. When there were any statistically significant genotype-by-group interactions \((p<0.05)\), post-hoc analyses were performed with ANOVA or Chi-square test, adjusting significant \(p\)-values by number of comparisons \((p<0.016 \text{ [three patient group]})\).

Finally, the effects of GCLC genotype (high-risk or low-risk) on dACC GSH levels and on the associations between GSH and glutamatergic neurometabolite levels in the dACC were examined by 2-tailed \(t\)-test in the whole patient sample.
Results

Clinical and demographic characteristics of participants

A total of 98 participants were included in this study, which consisted of 24 CLZ non-responders, 27 CLZ responders, 21 FLR, and 26 HCs. All participants were enrolled from our previous study that examined the relationship between glutamatergic neurometabolite levels and treatment response to antipsychotics including CLZ in patients with schizophrenia. Clinical and demographic characteristics of the participants are presented in Table 1. HCs showed a lower ratio of tobacco use compared to the patient groups. CPZ daily doses were higher in CLZ non-responders compared to FLR. CLZ non-responders showed higher symptom severity scores compared to CLZ responders and FLR. Six GSH data points (1 patient with CLZ non-responder, 3 CLZ-responders, 1 FLR, and 1 HC) were excluded from the analysis due to poor data quality. Eight participants did not agree to provide blood samples for genotyping (4 CLZ non-responders, 2 CLZ-responders, and 2 FLR).

GSH levels and spectrum quality indices

FWHM values and GM ratio were not different between the groups (Table 2). The relationships between participants’ clinical and demographic characteristics, GM ratios, and GSH levels are displayed in Supplementary Table 1. GM ratios were associated with dACC GSH levels in HCs while no other correlations were found. GSH levels in the dACC were not different among the groups (Figure 1). The result did not change after controlling for age, GM ratio, or FWHM (Table 2). Further, the results did not change after controlling for tobacco use for patient groups to consider its effects on antipsychotic levels, including CLZ.

Relationships between GSH levels and psychopathological scales

GSH levels in the dACC were not related to any symptom severity scores either within each group or the whole patient sample (Supplementary Table 2). The results remained unchanged after controlling for age, sex, tobacco use, and CPZ daily dose.

Correlations between GSH and Glu in the dACC

CLZ non-responders and HCs showed positive correlation between Glu and GSH levels in the dACC (Figure 2). Regarding the differences in the correlation of Glu x GSH between the groups by the r-to-z calculation, FLR showed a more negative correlation compared to CLZ non-responders (corrected-\( p=0.006 \)) and to HCs (corrected-\( p=0.004 \)). Regarding the correlations between Glx and GSH, not a significant correlation was observed in any group. FLR had a more negative correlation compared to HCs (corrected-\( p=0.04 \)). When partial correlation analyses were applied controlling for duration of illness, the difference between FLR and CLZ non-responders in the GSH x Glx correlation became significant (corrected-\( p=0.01 \)). Correlations between GSH and the other neurometabolite levels were presented in the supplementary Figure 4. No significant between-group differences were observed in the other neurometabolites in the correlations to GSH.
GCLC genotype in patients

A group difference was found in proportion of high-risk or low-risk GCLC genotypes between the patient groups (p=0.039). Post-hoc analyses found a higher ratio of the high-risk genotype in CLZ responders compared to CLZ non-responders (Odd’s ratio [OR]=5.25, corrected-p=0.042) (Table 3).

Effects of GCLC genotype on GSH levels and correlations between GSH and Glu levels

There was no difference in GSH levels between patients with high-risk GCLC genotype and patients with low-risk GCLC genotype. The results did not change when only Caucasian patients were included in the analysis (Supplementary Table 3). Associations between GSH and Glu (and Glx) levels were not different between the groups (Supplementary Figure 5).

Discussion

This study examined the relationships between dACC GSH levels and treatment response to antipsychotics, including CLZ, in patients with schizophrenia. We did not find any differences in dACC GSH levels among CLZ non-responders, CLZ responders, FLR, and HCs. Further, GSH levels were not related to symptom severity in any of the groups. However, this study revealed different relationships between GSH and Glu (and Glx) levels in the dACC between groups; FLR showed a more negative relationship compared to HCs. In addition, a higher proportion of individuals with high-risk GCLC genotype were observed in CLZ responders compared to CLZ non-responders. However, the previously reported effects of GCLC genotype on ACC GSH levels were not observed in this study.

A recent meta-analysis focusing on $^1$H-MRS studies reported lower GSH levels in patients with schizophrenia compared to HCs, with a small effect size (ES=0.26). Of the included 12 studies in this meta-analysis, ten did not find any differences in ACC GSH levels between patients with schizophrenia and HCs, which is consistent with our results. On the other hand, two studies have reported lower GSH levels in patients with schizophrenia compared to HCs. Regarding their ROIs, both studies placed their ROIs on the rostral area of the ACC, while the current study examined the dACC. It should be noted that among the studies assessing Glu levels in patients with schizophrenia, alterations may be more apparent in the rostral, compared to dorsal, area of the ACC.

In addition, these two studies included individuals with relatively younger participants with a short duration of illness. In the study by Do et al., two thirds of the patients had an illness duration that was shorter than 3 years (mean age of the patients was not reported). The mean age and duration of illness of patients were 27.2 and 4.5 years, respectively, in the study by Kumar et al. On the other hand, the mean age and the duration of illness of our study was 43.6 and 20.0 years, respectively. Although the aforementioned meta-analysis noted no significant association between ACC GSH levels and age or duration of illness, aging and illness chronicity may account for our null finding related to dACC GSH levels. Furthermore, Kumar et al. found that the effect size of lower GSH levels was larger in those with residual schizophrenia than those with non-residual schizophrenia, and that the former group was largely responsible for their finding of lower ACC GSH levels compared with HCs. They included patients with a score ≥2 on the Signs and Symptoms of Psychotic Illness (SSPI) global negative scale (range 1 to 4) in the residual group. Comparatively, our subjects in FLR and CLZ-responder groups showed less severe negative symptoms; average PANSS negative scores were
16 out of 49. Therefore, the null finding of this study could partly be attributed to the location of ACC ROI, age, and duration of illness of the included patients, and the lack of residual type in our sample.

We did not find any relationships between GSH levels and symptom severity measures. To our knowledge, there has been only one study reporting the association between symptom severities and GSH levels, as measured by $^1$H-MRS, in patients with schizophrenia. The authors noted a negative relationship between the Scale for the Assessment of Negative Symptoms (SANS) total score and GSH level in patients with schizophrenia. The relationship between GSH levels and symptom severity remains unclear at present. However, it should be noted that the present study included patients either showing response or non-response to antipsychotic treatment. Therefore, there was a lack of patients with moderate symptom severity. Therefore, the relationships between GSH levels and symptom severities still remain unclear. Further studies are needed to examine these relationships using larger samples with various symptom severity measures and across different illness phases.

Thus far, two studies investigated the correlations between GSH and Glu in patients with schizophrenia. One study reported a positive correlation between ACC GSH and Glu levels both in patients with schizophrenia and HCs. The other study also reported a positive correlation between these in patients with schizophrenia and HCs who had the GCLC low-risk genotype. Consistent with these findings, we found that HCs showed a positive relationship between them. On the other hand, FLR showed a negative relationship between GSH and Glu levels, which is in contrast to the findings from the aforementioned previous studies. In addition, such different relationships between the groups were not observed in the other neurometabolite, suggesting that the differences were not sporadic or simply related to water. However, it should be noted that the previous studies did not classify patients based on antipsychotic response and, accordingly, could include a mixed sample as compared to our sample which was categorized based on status of treatment resistance. Regarding the findings in this study, there are several possible interpretations. FLR may have aberrant functioning in the GSH synthesizing cycle (i.e. γ-glutamyl cycle) or GSH-Glu cycle as a reflection of underlying pathophysiology in comparison with CLZ non-responders and HCs; through the γ-glutamyl cycle, GSH is synthesized from the precursor amino acids Glu, cysteine, and glycine in the cytosol, and also GSH was reported to serve as a reservoir of neural glutamate. Alternatively, the administration of CLZ might be responsible for the differences between groups. We observed a negative relationship between GSH and Glu levels only in FLR, while CLZ-treated participants (both CLZ non-responders and CLZ responders) showed numerically positive relationships, which is similar to that observed in HCs. According to Lee et al., four previous post-mortem studies consistently found elevations in expression of a gene coding for a subunit of the GSH synthesis enzyme, glutamate-cysteine ligase modifier (GCLM), in brains of CLZ-treated patients with schizophrenia compared to non-CLZ treated patients. Thus, it may be possible that CLZ has modulating effects on GSH-Glu neurotransmission by affecting GCLM expression. Still, it remains unclear what mechanism underlies the difference in the correlations between GSH and Glu levels based on antipsychotic treatment response.

Our study demonstrated a higher proportion of high-risk GCLC genotype in CLZ responders compared to CLZ non-responders. However, it should be noted that the study also included participants with different ethnicities. First, the classification of high risk/low risk of GCLC genotype...
was provided based on European Caucasian populations (Swiss and Danish). In addition, the probabilities of variance of GCLC genotypes were significantly different between ethnicities. Further studies are warranted to assess the effects of GCLC genotypes on the risk of schizophrenia and response to antipsychotic treatment, including non-Caucasian ethnicities.

We did not find any effects of GCLC genotypes on GSH levels or on correlations between GSH and glutamatergic neurometabolite levels in the dACC. Our null findings may partially be attributable to the mixed ethnicities of our study as the previous study by Xin et al. included only European Caucasian samples. It was only in low-risk genotype samples that the authors found lower ACC GSH levels in patients compared to HCs and a positive correlation between GSH and Glu levels in the ACC. Moreover, participants in the present study consisted of chronically medicated patients, while Xin et al. included Caucasian patients in earlier stages of illness (mean=2.6 year). Furthermore, as previously mentioned, both GSH and Glu levels in the dACC might be affected by antipsychotics including CLZ. Thus, these factors may have led to our null finding regarding a relationship between GCLC genotypes and GSH levels or correlations between GSH and Glu levels in the dACC.

There are several limitations to our study. First, $^1$H-MRS is unable to differentiate neurotransmitter or vesicular and metabolic pools of neurometabolites. Second, although neurochemical levels were corrected for CSF fraction, relaxation effects were not considered in this study. Third, due to a cross-sectional design of this study, we failed to assess the impact of the long-term illness and accumulated doses of antipsychotics on the neurochemical levels. Fourth, although this study has included 98 participants, each group consisted of a small sample size. Finally, owing to the cross-sectional design of this study, we were not able to determine the causal relationships between GSH levels and antipsychotic treatment. This question may be better answered through studies employing a prospective, longitudinal design. Other limitations are detailed in Supplementary Discussion.

In conclusion, the main findings of this cross-sectional $^1$H-MRS study were: (1) there was no identified difference in dACC GSH levels among CLZ non-responders, CLZ responders, FLR, or HCs; (2) FLR showed a negative relationship between GSH and Glu levels in the dACC, whereas positive associations were found in HCs; and (3) CLZ responders had a higher ratio of high-risk GCLC genotypes compared to CLZ non-responders. Future studies are warranted to further elucidate neuroimaging correlates of TRS and the mechanisms of action for CLZ.
Conflict of Interest:

Y.I. has received fellowship grants from Canadian Institute of Health Research (CIHR), Keio University Medical Science Foundation, Mitsukoshi Foundation, and manuscript fees from Dainippon Sumitomo Pharma. S.N. has received fellowship grants from CIHR, research support from Japan Society for the Promotion of Science, Japan Agency for Medical Research and development (AMED), Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daichi Sankyo Scholarship Donation Program within the past three years. He has also received research supports, manuscript fees or speaker's honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. E.P. has received research support from an Ontario Graduate Scholarship (OGS), a CIHR Canada Graduate Scholarship – Master's, and a CIHR Vanier Canada Graduate Scholarship. P.T. A.B. F.C. has received fellowship grants from CIHR and OGS. J.K. has received research support from OGS. P.S. reports no conflicts of interest. S.C. G.R. is currently receiving research funding from CIHR and HLS Therapeutics. P.G. has received research support from CIHR, OHMF, Ontario AHSC AFP Innovation Fund, and CAMH. V.D. N.P. A.G. has received research support from the following external funding agencies: the CIHR, US NIH, OMHF, NARSAD, Mexico Instituto de Ciencia y Tecnología del Distrito Federal, Consejo Nacional De Ciencia Y Tecnología, Ministry of Economic Development and Innovation of Ontario, Ontario AHSC AFP Innovation Fund and W. Garfield Weston Foundation. Other authors have no financial or other relationship relevant to the subject of this manuscript.

Author’s Contributors:

Study concept and design: Y.I., S.N., G.R., P.G., A.G.

Acquisition of data: Y.I., S.N., E.P., P.T., A.B., W.M., S.C., V.D., N.P.

Analysis and interpretation of data: Y.I., S.N., E.P., P.T., A.B., S.C., V.D., N.P.

Drafting of the manuscript: Y.I., S.N., A.G.

Statistical analysis: Y.I., S.N., A.G.

Critical revision of the manuscript for important intellectual content: Y.I., S.N., E.P., P.T., A.B., F.C., J.K., P.S., S.C., G.R., P.G., V.D., N.P., A.G.

Obtained funding: S.N., P.G., A.G.

Administrative, technical and material support: W.M.

Study supervision: G.R., P.G., A.G.
References

1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Archives of general psychiatry* Dec 2003;60(12):1187-1192.
2. Frangou S. Schizophrenia. *Medicine* 2008;36(8):405-409.
3. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. *Science (New York, NY)* Jun 20 1975;188(4194):1217-1219.
4. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. *Lancet* Oct 28 1995;346(8983):1130-1131.
5. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. *Archives of general psychiatry* Aug 2012;69(8):776-786.
6. Caravaggio F, Borlido C, Wilson A, Graff-Guerrero A. Examining endogenous dopamine in treated schizophrenia using [(1)(1)C]-(+)-PHNO positron emission tomography: A pilot study. *Clinica chimica acta: international journal of clinical chemistry* Sep 20 2015;449:60-62.
7. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. *Archives of general psychiatry* Mar 2010;67(3):231-239.
8. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. *Proceedings of the National Academy of Sciences of the United States of America* Jul 5 2000;97(14):8104-8109.
9. Amato D, Kruyer A, Samaha AN, Heinz A. Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. *Frontiers in psychiatry* 2019;10:314.
10. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. *The American journal of psychiatry* Nov 2012;169(11):1203-1210.
11. Kim E, Howes OD, Veronese M, et al. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* Mar 2017;42(4):941-950.
12. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Archives of general psychiatry* Mar 1994;51(3):199-214.
13. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* Aug 1995;13(1):9-19.
14. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. *Biol Psychiatry* Mar 01 2014;75(5):e11-13.

15. Mouchlianitis E, Bloomfield MA, Law V, et al. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. *Schizophrenia bulletin* May 2016;42(3):744-752.

16. Tarumi R, Tsugawa S, Noda Y, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. *Neuropsychopharmacology* : official publication of the American College of Neuropsychopharmacology Mar 2020;45(4):632-640.

17. Egerton A, Broberg BV, Van Haren N, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). *Molecular psychiatry* Jun 7 2018.

18. Iwata Y, Nakajima S, Plitman E, et al. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. *Biol Psychiatry* Sep 26 2018.

19. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH. NMDA receptor channels: subunit-specific potentiation by reducing agents. *Neuron* May 1994;12(5):1031-1040.

20. Sedlak TW, Paul BD, Parker GM, et al. The glutathione cycle shapes synaptic glutamate activity. *Proceedings of the National Academy of Sciences of the United States of America* Feb 12 2019;116(7):2701-2706.

21. Tsugawa S, Noda Y, Tarumi R, et al. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. *Journal of psychopharmacology (Oxford, England)* Oct 2019;33(10):1199-1214.

22. Hardingham GE, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. *Nature reviews Neuroscience* Feb 2016;17(2):125-134.

23. Tsugawa S, Noda Y, Tarumi R, et al. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. *J Psychopharmacol* Apr 30 2019;26988119845820.

24. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. *Progress in neuro-psychopharmacology & biological psychiatry* Oct 1 2009;33(7):1178-1183.

25. Wang M, Yao Y, Kuang D, Hampson DR. Activation of family C G-protein-coupled receptors by the tripeptide glutathione. *The Journal of biological chemistry* Mar 31 2006;281(13):8864-8870.

26. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. *The*
27. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. *Proceedings of the National Academy of Sciences of the United States of America* Oct 16 2007;104(42):16621-16626.

28. Xin L, Mekle R, Fournier M, et al. Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis. *Schizophrenia bulletin* Sep 2016;42(5):1185-1196.

29. Das TK, Javadzadeh A, Dey A, Sabesan P, Theberge J, Radiu J, Palaniyappan L. Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. *Progress in neuro-psychopharmacology & biological psychiatry* Aug 17 2018.

30. Hendouei N, Farnia S, Mohseni F, et al. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone. *Biomed Pharmacother* Jul 2018;103:965-972.

31. Pinheiro DS, Santos RDS, de Brito RB, Cruz A, Ghedini PC, Reis AAS. GSTM1/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients. *PLoS One* 2017;12(8):e0183812.

32. Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. *The American journal of psychiatry* Mar 01 2017;174(3):216-229.

33. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *The Journal of clinical psychiatry* 1998;59 Suppl 20:22-35;quiz 34-57.

34. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. *NMR in biomedicine* Oct 1998;11(6):266-272.

35. Shungu DC, Weiduschat N, Murrough JW, et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. *NMR in biomedicine* Sep 2012;25(9):1073-1087.

36. Da Silva T, Hafizi S, Andreazza AC, et al. Glutathione, the Major Redox Regulator, in the Prefrontal Cortex of Individuals at Clinical High Risk for Psychosis. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum* Apr 1 2018;21(4):311-318.

37. Wright SM, Wald LL. Theory and application of array coils in MR spectroscopy. *NMR in biomedicine* Dec 1997;10(8):394-410.

38. Shungu DC. N-acetylcysteine for the treatment of glutathione deficiency and oxidative stress in schizophrenia. *Biol Psychiatry* Jun 1
39. Markwardt CB. Non-Linear Least Squares Fitting in IDL with MPFIT. In: Bohlender DA, Durand D, Patrick D, eds. Astronomical Data Analysis Software and Systems XVIII: 2009:251-254.
40. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR in biomedicine Jun 2001;14(4):260-264.
41. Woolrich MW, Jbabdi S, Patenaude B, et al. Bayesian analysis of neuroimaging data in FSL. NeuroImage Mar 2009;45(1 Suppl):S173-186.
42. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J, Graff-Guerrero A. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Aug 2011;36(9):1781-1791.
43. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. The European journal of neuroscience Oct 2000;12(10):3721-3728.
44. Kumar J, Liddle EB, Fernandes CC, et al. Glutathione and glutamate in schizophrenia: a 7T MRS study. Molecular psychiatry Jun 22 2018.
45. Matsuzawa D, Obata T, Shirayama Y, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 2008;3(4):e1944.
46. Dringen R. Metabolism and functions of glutathione in brain. Progress in neurobiology Dec 2000;62(6):649-671.
47. Lee BJ, Marchionni L, Andrews CE, et al. Analysis of differential gene expression mediated by clozapine in human postmortem brains. Schizophrenia research Jul 2017:185:58-66.
48. Walsh AC, Feulner JA, Reilly A. Evidence for functionally significant polymorphism of human glutamate cysteine ligase catalytic subunit: association with glutathione levels and drug resistance in the National Cancer Institute tumor cell line panel. Toxicol Sci Jun 2001;61(2):218-223.
49. Gasparovic C, Song T, Devier D, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med Jun 2006;55(6):1219-1226.
Figure 1. GSH levels in the dACC

[Figure]

Abbreviations: CLZ, clozapine; dACC, dorsal anterior cingulate cortex; FLR, first-line responder; GSH, glutathione; HC, healthy control; IU, institutional unit

Figure 2. Relationships between GSH and Glu and Glx in each group

[Figure]

Abbreviations: CLZ, clozapine; dACC, dorsal anterior cingulate cortex; FLR, first-line responder; Glu, glutamate; Glx, glutamate+glutamine; GSH, glutathione; HC, healthy control; IU, institutional unit
Table 1. Characteristics of participants

|                          | CLZ non-responders (n = 24) | CLZ responders (n = 27) | FLR (n = 21) | HCs (n = 26) | ANOVA or Chi-Square |
|--------------------------|-----------------------------|------------------------|--------------|--------------|---------------------|
|                          | Mean ± SD or n (%)          | Mean ± SD or n (%)     | Mean ± SD or n (%) | Mean ± SD or n (%) | F value or df  | p value      |
| Age, year                | 44.8 ± 13.2                 | 40.5 ± 11.2            | 46.3 ± 12.7  | 40.8 ± 13.2  | F(3.94) = 0.87     | 0.46         |
| Female                   | 5 (20.8)                    | 8 (29.6)               | 5 (23.8)     | 7 (26.9)     | 3                   | 0.90         |
| Tobacco use              | 10 (41.7)                   | 12 (44.4)              | 13 (61.9)    | 1 (3.8)      | 3                   | 0.0003 a     |
| DUI, year                | 23.5 ± 13.2                 | 16.4 ± 9.7             | 20.0 ± 12.2  |              | F(2.69) = 2.53     | 0.09         |
| CPZ equivalent dose, mg/day* | 643.7 ± 186.5       | 527.1 ± 201.7          | 443.1 ± 188.1|              | F(2.69) = 6.18     | 0.003 b      |
| CLZ dose, mg/day         | 429.1 ± 124.3               | 351.4 ± 134.5          |              |              | F(1.50) = 4.56     | 0.04         |
| PANSS total score        | 82.7 ± 12.0                 | 56.1 ± 10.9            | 57.2 ± 9.5   |              | F(2.69) = 45.91    | < 0.0001 c   |
| Positive subscale        | 22.5 ± 4.0                  | 11.5 ± 2.0             | 10.9 ± 2.3   |              | F(2.69) = 122.35   | < 0.0001 c   |
| Negative subscale        | 20.6 ± 4.3                  | 16.1 ± 4.8             | 16.0 ± 3.6   |              | F(2.69) = 8.90     | < 0.0001 d   |
| General subscale         | 39.6 ± 7.2                  | 28.5 ± 5.6             | 30.3 ± 4.7   |              | F(2.69) = 24.70    | < 0.0001     |
Significant p-values were set as $< 0.005 (0.05/10)$

* Antipsychotics: First-line responders were on flupenthixol (n = 1), haloperidol (n = 2), loxapine (n = 1), olanzapine (n = 8), paliperidone (n = 1), risperidone (n = 1), ziprasidone (n = 1), flupenthixol LAI (n = 2), fluphenazine LAI (n = 1), paliperidone LAI (n = 1), or risperidone LAI (n = 2).

Followings were Bonferroni-corrected p-values $< 0.05$

a, CLZ non-responders > HCs (p = 0.01), CLZ responders > HC (p = 0.005), FLR > HCs (p < 0.001)

b, CLZ non-responders > FLR (p = 0.003)

c, CLZ non-responders > CLZ responders (p < 0.001), CLZ non-responders > FLR (p < 0.001)

d, CLZ non-responders > CLZ responders (p = 0.001), CLZ non-responders > FLR (p = 0.002)

Abbreviations: ANOVA, analyses of variance; CGI-S, Clinical Global Impression Severity scale; CLZ, clozapine; CPZ, chlorpromazine; DUI, duration of illness; FLR, first-line responders; HCs, healthy controls; LAI, long-acting injection; PANSS, Positive and Negative Syndromes Scale; SD, standard deviation
Table 2. GSH levels in the dACC and scan quality indices between groups

|                     | CLZ non-responders | CLZ responders | FLR | HCs | ANOVA with age covariate | ANCOVA with GM/(GM+WM) covariate |
|---------------------|--------------------|----------------|-----|-----|--------------------------|----------------------------------|
|                     | (n = 23)           | (n = 24)       | (n = 20) | (n = 25) |                           |                                   |
| Mean ± SD           | Mean ± SD          | Mean ± SD      | Mean ± SD | Mean ± SD | F value                  | p value                          | F value | p value |
| GSH x 10^{-3}, IU   | 2.26 ± 0.67        | 2.37 ± 0.72    | 2.20 ± 0.50 | 2.22 ± 0.57 | F(3,88) = 0.34          | 0.80                             | F(3,87) = 0.46          | 0.71 |
| GM/(GM+WM)          | 0.70 ± 0.06        | 0.70 ± 0.03    | 0.71 ± 0.03 | 0.69 ± 0.04 | F(3,88) = 0.63          | 0.60                             | F(3,87) = 0.60          | 0.60 |
| FWHM                | 7.04 ± 1.15        | 7.13 ± 1.15    | 7.45 ± 1.00 | 7.36 ± 1.15 | F(3,88) = 0.61          | 0.61                             | F(3,87) = 0.61          | 0.61 |

Abbreviations; ANOVA, analysis of variance; CLZ, clozapine; dACC, dorsal anterior cingulate cortex; FLR, first-line responders; FWHM, full-width at half maximum; GM, gray matter; GSH, glutathione; HCs, healthy controls; IU, institutional units; SD, standard deviation; WM, white matter
Table 3. GCLC GAG TNR genotypes and ethnicity in patient groups

|                  | CLZ non-responders | CLZ responders | FLR  | Chi-Square |
|------------------|--------------------|----------------|------|------------|
|                  | n (%)              | n (%)          | n (%)| df         | p value |
| Genotypes        | n = 19             | n = 25         | n = 19| 2          | 0.041 a |
| High-risk (7/8, 8/8, 8/9, 9/9) | 10 (50.0)         | 21 (84.0)      | 11 (57.9)|           |         |
| Low-risk (7/7, 7/9)   | 10 (50.0)         | 4 (16.0)       | 8 (42.1)|           |         |
| Genotypes (only with Caucasian) | n = 13          | n = 21         | n = 17| 2          | 0.052   |
| High-risk (7/8, 8/8, 8/9, 9/9) | 8 (61.5)          | 19 (90.5)      | 10 (58.8)|           |         |
| Low-risk (7/7, 7/9)   | 5 (38.5)          | 2 (9.5)        | 7 (41.2)|           |         |
| Ethnicity         | n = 20             | n = 25         | n = 19| 8          | 0.16    |
| Caucasian         | 13 (65.0)          | 21 (84.0)      | 17 (89.4)|           |         |
| African descent   | 1 (5.0)            | 1 (4.0)        | 1 (5.3)|           |         |
| East/southeast Asian | 0                | 2 (8.0)        | 0     |            |         |
| Hispanic          | 2 (10.0)           | 0              | 0     |            |         |
| Other             | 4 (20.0)           | 1 (4.0)        | 1 (5.3)|            |         |
| Ethnicity         | n = 20 | n = 25 | n = 19 | 3  | 0.44 |
|------------------|--------|--------|--------|----|------|
| Caucasian        | 13 (65.0) | 21 (84.0) | 17 (89.4) |    |      |
| Non-Caucasian    | 7 (35.0)  | 4 (16.0)  | 2 (10.6)  |    |      |

a, Higher ratio of hi-risk genotypes was observed in CLZ responders compared to CLZ non-responders (corrected-p = 0.042)

Abbreviations: CLZ, clozapine; FLR, first-line responders; GCLC, glutamate-cysteine ligase; TNR, trinucleotide
Figure 2-2